NPI: 1124084678 · MERRILL, WI 54452 · Certified Registered Nurse Anesthetist · NPI assigned 04/25/2006
Authorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
| Authorized Official | YANG, JERRY (SVP & CHIEF FINANCIAL OFFICER) |
| NPI Enumeration Date | 04/25/2006 |
Other providers sharing the same authorized official: YANG, JERRY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 26,817 | $1.55M |
| 2019 | 26,833 | $1.41M |
| 2020 | 22,138 | $1.28M |
| 2021 | 26,993 | $1.42M |
| 2022 | 28,216 | $1.61M |
| 2023 | 30,627 | $1.97M |
| 2024 | 26,777 | $1.87M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 4,602 | 3,482 | $1.95M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 8,138 | 6,030 | $1.17M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7,985 | 6,763 | $1.07M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7,092 | 4,847 | $1.02M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9,286 | 8,214 | $978K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 5,617 | 4,474 | $848K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2,710 | 2,032 | $551K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2,832 | 2,428 | $523K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,732 | 1,471 | $451K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,829 | 1,483 | $375K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,793 | 1,487 | $281K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2,231 | 1,961 | $229K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1,963 | 1,710 | $219K |
| 99215 | Prolong outpt/office vis | 1,365 | 1,199 | $216K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 667 | 568 | $160K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1,451 | 1,032 | $149K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 345 | 275 | $119K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,151 | 915 | $78K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,028 | 868 | $76K |
| 80053 | Comprehensive metabolic panel | 9,131 | 6,901 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 10,219 | 7,660 | $47K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,813 | 2,120 | $44K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 474 | 437 | $43K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,508 | 1,238 | $37K |
| 87070 | 3,318 | 2,919 | $31K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 741 | 585 | $28K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2,042 | 1,814 | $27K |
| 84484 | 4,748 | 3,105 | $26K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 542 | 446 | $24K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 898 | 650 | $24K |
| 87430 | 1,630 | 1,436 | $24K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 82 | 64 | $17K |
| 83690 | 3,087 | 2,456 | $14K | |
| 83735 | 3,938 | 2,821 | $14K | |
| 81001 | 6,365 | 5,066 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2,186 | 1,643 | $12K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 52 | 42 | $11K |
| 80306 | 911 | 725 | $10K | |
| 81025 | 1,123 | 961 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,794 | 1,465 | $9K |
| 83880 | 711 | 559 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 946 | 738 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 65 | 45 | $8K |
| 83605 | 1,634 | 1,172 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | 768 | 618 | $8K |
| 86140 | 2,579 | 1,965 | $8K | |
| 85610 | 3,077 | 2,312 | $6K | |
| 87040 | 1,030 | 631 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 77 | 66 | $5K |
| 85379 | 898 | 750 | $5K | |
| 87077 | 972 | 805 | $5K | |
| 85730 | 1,870 | 1,443 | $5K | |
| 84703 | 761 | 662 | $5K | |
| 96368 | 26 | 24 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 14 | 14 | $3K |
| 84145 | 318 | 268 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | 1,823 | 1,524 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,640 | 3,568 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 63 | 53 | $3K |
| 85027 | 904 | 671 | $3K | |
| 87420 | 146 | 131 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5,744 | 4,268 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 191 | 83 | $2K |
| 82948 | 649 | 257 | $1K | |
| 71045 | Radiologic examination, chest; single view | 3,741 | 3,014 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 90 | 53 | $1K |
| G0378 | Hospital observation service, per hour | 14 | 12 | $1K |
| 87186 | 332 | 257 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,607 | 1,300 | $1K |
| 85007 | 967 | 767 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 20 | 15 | $1K |
| 82805 | 51 | 40 | $993.33 | |
| 87081 | 136 | 125 | $961.56 | |
| 87400 | 146 | 120 | $878.81 | |
| 87088 | 201 | 169 | $829.19 | |
| 85652 | 448 | 336 | $783.42 | |
| 82803 | 64 | 43 | $773.76 | |
| 36415 | Collection of venous blood by venipuncture | 5,212 | 3,823 | $744.08 |
| 82150 | 141 | 114 | $651.13 | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 13 | 13 | $537.38 |
| 73630 | 157 | 143 | $478.88 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 4,300 | 3,288 | $452.20 |
| 82550 | 68 | 57 | $261.89 | |
| 82728 | 16 | 15 | $152.24 | |
| 36000 | 271 | 244 | $113.27 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,194 | 2,365 | $91.76 |
| 81003 | 72 | 49 | $72.86 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 3,414 | 2,431 | $65.18 |
| 73610 | 29 | 29 | $53.52 | |
| 96376 | 762 | 589 | $50.21 | |
| 83615 | 14 | 13 | $44.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,760 | 1,992 | $42.21 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,774 | 2,115 | $35.33 |
| 81015 | 29 | 19 | $31.69 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 183 | 139 | $10.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 396 | 287 | $5.44 |
| A9270 | Non-covered item or service | 3,065 | 1,558 | $3.59 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 496 | 388 | $0.08 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 235 | 190 | $0.08 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 29 | 26 | $0.00 |
| 73130 | 13 | 13 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 443 | 351 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 704 | 564 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 17 | 15 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 14 | 12 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 438 | 301 | $0.00 |